Search
forLearn
5 / 801 resultslearn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn octapeptide-2
learn ACETYL TETRAPEPTIDE-2
Research
5 / 1000+ resultsresearch A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Induction of versican by ascorbic acid 2-phosphate in dermal papilla cells
Vitamin C derivative increases versican in cells, potentially aiding hair growth.
research Estudio de 2 suplementos nutricionales (cápsulas y espray) en el tratamiento de la alopecia femenina. Estudio KAIDAX
Two nutritional supplements improved hair growth and reduced hair loss in women with hair loss conditions.
research Alteration of Skin Properties with Autologous Dermal Fibroblasts
Using your own skin cells can help repair aging skin and promote hair growth.
Community Join
5 / 1000+ resultscommunity Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.